| PLCG1 mutations in cutaneous T-cell lymphomas JP Vaqué, G Gómez-López, V Monsálvez, I Varela, N Martínez, C Pérez, ... Blood, The Journal of the American Society of Hematology 123 (13), 2034-2043, 2014 | 237 | 2014 |
| NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells L Odqvist, M Sánchez-Beato, S Montes-Moreno, E Martín-Sánchez, ... Clinical Cancer Research 19 (9), 2319-2330, 2013 | 71 | 2013 |
| NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma L Odqvist, S Montes-Moreno, RE Sánchez-Pacheco, KH Young, ... Modern pathology 27 (10), 1331-1337, 2014 | 40 | 2014 |
| CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer E Martín-Sánchez, S Mendaza, A Ulazia-Garmendia, ... Oncotarget 8 (9), 15789, 2017 | 37 | 2017 |
| ADAM12 is a potential therapeutic target regulated by hypomethylation in triple-negative breast cancer S Mendaza, A Ulazia-Garmendia, I Monreal-Santesteban, A Córdoba, ... International journal of molecular sciences 21 (3), 903, 2020 | 36 | 2020 |
| Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas E Martín-Sánchez, SM Rodríguez-Pinilla, M Sánchez-Beato, L Lombardía, ... Haematologica 98 (1), 57, 2013 | 32 | 2013 |
| Absence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix S Mendaza, J Fernández-Irigoyen, E Santamaría, T Zudaire, R Guarch, ... International journal of molecular sciences 21 (6), 2125, 2020 | 26 | 2020 |
| PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases E Martín-Sánchez, L Odqvist, SM Rodríguez-Pinilla, M Sánchez-Beato, ... PLoS One 9 (11), e112148, 2014 | 25 | 2014 |
| Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma R Termini, D Žihala, E Terpos, A Perez-Montaña, T Jelínek, M Raab, ... Clinical Cancer Research 28 (21), 4771-4781, 2022 | 24 | 2022 |
| CDH22 hypermethylation is an independent prognostic biomarker in breast cancer E Martín-Sánchez, S Mendaza, A Ulazia-Garmendia, ... Clinical Epigenetics 9, 1-8, 2017 | 20 | 2017 |
| Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies LE Tamariz-Amador, AM Battaglia, C Maia, A Zherniakova, C Guerrero, ... Blood Cancer Journal 11 (12), 202, 2021 | 19 | 2021 |
| Immunological biomarkers of fatal COVID-19: a study of 868 patients E Martin-Sanchez, JJ Garces, C Maia, S Inoges, A Lopez-Diaz de Cerio, ... Frontiers in Immunology 12, 659018, 2021 | 19 | 2021 |
| Immunologic characterization of COVID-19 patients with hematological cancer C Maia, E Martín-Sánchez, JJ Garcés, ALD De Cerio, S Inogés, ... Haematologica 106 (5), 1457, 2020 | 18 | 2020 |
| Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix I Blanco‐Luquin, R Guarch, A Ojer, N Pérez‐Janices, E Martín‐Sánchez, ... Pathology international 65 (9), 476-485, 2015 | 18 | 2015 |
| HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines. E Martín-Sánchez, M Sánchez-Beato, ME Rodríguez, ... British journal of haematology 152 (3), 2011 | 18 | 2011 |
| Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of … E Martín-Sánchez, E Pernaut-Leza, S Mendaza, A Cordoba, ... Virchows Archiv 469, 51-59, 2016 | 13 | 2016 |
| [Translated article] Epidemiology of Melanoma in Spain: Estimation of Number of Patients With Stage III Disease Eligible for Adjuvant Therapies E Nagore, D Moreno-Ramírez, P Ortiz-Romero, E Martín-Sánchez, ... Actas dermo-sifiliograficas 113 (4), T354-T362, 2022 | 5 | 2022 |
| Understanding the molecular mechanism of miR-877-3p could provide potential biomarkers and therapeutic targets in squamous cell carcinoma of the cervix S Mendaza, J Fernández-Irigoyen, E Santamaría, I Arozarena, ... Cancers 13 (7), 1739, 2021 | 5 | 2021 |
| Biological and clinical significance of undetectable circulating tumor cells (CTCs) in patients (pts) with multiple myeloma (MM) JJ Garcés, R Termini, E Martín-Sánchez, M Lasa, JJ Perez, NC Gutierrez, ... Blood 142, 646, 2023 | 3 | 2023 |
| A CD38/CD28xCD3 trispecific T-cell engager (TCE) as a potentially active agent in multiple myeloma patients relapsed and/or refractory (RRMM) to anti-CD38 monoclonal antibodies … A Zabaleta, L Blanco, P Kim, K Bisht, H Wang, HJ Van de Velde, M Lasa, ... Blood 142, 1921, 2023 | 3 | 2023 |
